Your session is about to expire
← Back to Search
Triple Therapy for Small Cell Lung Cancer
Study Summary
This trial is testing a new cancer treatment on patients who haven't responded to other treatments. It's divided into two parts, with the first part testing different doses to see what's safe and effective.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
In how many different settings is this research being conducted?
"This study is being conducted out of several hospitals, including the Indiana University Melvin and Bren Simon Cancer Center in Indianapolis, Indiana; the University of Minnesota in Minneapolis, Minnesota; and the University of Illinois Cancer Center in Chicago, Illinois."
Are investigators still looking for people to enroll in this experiment?
"The listed information on clinicaltrials.gov suggests that this trial is still open to new participants. The study was first advertised on September 6th, 2018 with the most recent update being October 26th, 2022."
What is the primary disease that Plinabulin seeks to alleviate?
"Plinabulin has applications in the treatment of anti-angiogenic therapy and malignant neoplasms. The medication can also help patients with unresectable melanoma or squamous cell carcinoma."
What are we trying to learn from this clinical trial?
"The primary outcome of this study is the maximum tolerated dose (MTD) over a 36-month period. Secondary outcomes include assessing adverse events, proportion of subjects with confirmed objective response, and clinical benefit rate."
What previous research has been conducted on Plinabulin?
"Plinabulin was first researched in 2009 at Texas Children's Hospital. There have been 368 completed studies on the medication since then and presently there are 798 active studies regarding plinabulin with many of these trials based out of Indianapolis, Indiana."
How many people are being treated as part of this study?
"As this study requires 35 individuals that satisfy the certain prerequisites, patients that meet these qualifications can enroll at various locations like the Indiana University Melvin and Bren Simon Cancer Center in Indianapolis or the University of Minnesota in Minneapolis."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger